Antimicrobial mechanisms of the urinary tract

Journal of Molecular Medicine

Volumn 86, Issue 1, 2008, Pages 37-47

  Chromek, Milan ^a   Brauner, Annelie ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antimicrobial peptides; Infection; Innate immunity; Kidney; Mucosal immunity; Urinary tract

Indexed keywords

BETA DEFENSIN 1; BETA DEFENSIN 2; LACTOFERRIN; POLYPEPTIDE ANTIBIOTIC AGENT; TAMM HORSFALL GLYCOPROTEIN;

ANTIMICROBIAL ACTIVITY; BACTERIAL COLONIZATION; FUNCTIONAL ANATOMY; HEALTH CARE PERSONNEL; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; MUCOSAL IMMUNITY; PATHOGENICITY; PERINEUM; PROTEIN EXPRESSION; REVIEW; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; UROTHELIUM; VESICOURETERAL REFLUX;

HUMANS; IMMUNITY, INNATE; URINARY TRACT; URINARY TRACT INFECTIONS;

EID: 38149109857     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0256-4     Document Type: Review

References (125)

1. Hooton TM, Scholes D, Stapleton AE, Roberts PL, Winter C, Gupta K, Samadpour M, Stamm WE (2000) A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med 343:992-997
2. Guyon F (1889) Note sur les conditions de réceptivité de l'appareil urinaire à l'invasion microbienne. Ann C Mal D Org Génitourin 7:257-262
3. Rovsing T (1898) Über die Ätiologie, Pathogenese und Behandlung der septischen Infektionen der Harnwege. Monatsber F Urol 3:503-535
4. Cox CE, Hinman F Jr (1961) Experiments with induced bacteriuria, vesical emptying and bacterial growth on the mechanism of bladder defense to infection. J Urol 86:739-748
5. Hess O (1913) Experimentelle Untersuchungen über die Bacterium coli-infektion der Harnorgane. Mitteil. A D Grenzeb D Med U Chir 26:135-175
6. Hagberg L, Engberg I, Freter R, Lam J, Olling S, Svanborg Eden C (1983) Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect Immun 40:273-283
7. Ronald A (2003) The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 49:71-82
8. Snyder JA, Haugen BJ, Buckles EL, Lockatell CV, Johnson DE, Donnenberg MS, Welch RA, Mobley HL (2004) Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect Immun 72:6373-6381
9. Tullus K, Jacobson SH, Katouli M, Brauner A (1991) Relative importance of eight virulence characteristics of pyelonephritogenic Escherichia coli strains assessed by multivariate statistical analysis. J Urol 146:1153-1155
10. Kaper JB, Nataro JP, Mobley HL (2004) Pathogenic Escherichia coli. Nat Rev Microbiol 2:123-140
11. Mulvey MA (2002) Adhesion and entry of uropathogenic Escherichia coli. Cell Microbiol 4:257-271
12. Nowicki B, Rhen M, Vaisanen-Rhen V, Pere A, Korhonen TK (1984) Immunofluorescence study of fimbrial phase variation in Escherichia coli KS71. J Bacteriol 160:691-695
13. Snyder JA, Haugen BJ, Lockatell CV, Maroncle N, Hagan EC, Johnson DE, Welch RA, Mobley HL (2005) Coordinate expression of fimbriae in uropathogenic Escherichia coli. Infect Immun 73:7588-7596
14. Wu XR, Sun TT, Medina JJ (1996) In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci USA 93:9630-9635
15. Connell I, Agace W, Klemm P, Schembri M, Marild S, Svanborg C (1996) Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci USA 93:9827-9832
16. Bergsten G, Wullt B, Schembri MA, Leijonhufvud I, Svanborg C (2007) Do type 1 fimbriae promote inflammation in the human urinary tract? Cell Microbiol 9(7):1766-1781
17. Gunther NW, Lockatell V, Johnson DE, Mobley HL (2001) In vivo dynamics of type 1 fimbria regulation in uropathogenic Escherichia coli during experimental urinary tract infection. Infect Immun 69:2838-2846
18. Soderhall M, Bergerheim US, Jacobson SH, Lundahl J, Mollby R, Normark S, Winberg J (1997) Molecular evidence for pap-G specific adhesion of Escherichia coli to human renal cells. J Urol 157:346-350
19. Olsen A, Jonsson A, Normark S (1989) Fibronectin binding mediated by a novel class of surface organelles on Escherichia coli. Nature 338:652-655
20. Gophna U, Barlev M, Seijffers R, Oelschlager TA, Hacker J, Ron EZ (2001) Curli fibers mediate internalization of Escherichia coli by eukaryotic cells. Infect Immun 69:2659-2665
21. Marre R, Kreft B, Hacker J (1990) Genetically engineered S and F1C fimbriae differ in their contribution to adherence of Escherichia coli to cultured renal tubular cells. Infect Immun 58:3434-3437
22. Selvarangan R, Goluszko P, Singhal J, Carnoy C, Moseley S, Hudson B, Nowicki S, Nowicki B (2004) Interaction of Dr adhesin with collagen type IV is a critical step in Escherichia coli renal persistence. Infect Immun 72:4827-4835
23. Allison C, Emody L, Coleman N, Hughes C (1994) The role of swarm cell differentiation and multicellular migration in the uropathogenicity of Proteus mirabilis. J Infect Dis 169:1155-1158
24. Ramos HC, Rumbo M, Sirard JC (2004) Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol 12:509-517
25. Wright KJ, Seed PC, Hultgren SJ (2005) Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infect Immun 73:7657-7668
26. Jacobson SH, Tullus K, Wretlind B, Brauner A (1988) Aerobactin-mediated uptake of iron by strains of Escherichia coli causing acute pyelonephritis and bacteraemia. J Infect 16:147-152
27. Jones BD, Lockatell CV, Johnson DE, Warren JW, Mobley HL (1990) Construction of a urease-negative mutant of Proteus mirabilis: analysis of virulence in a mouse model of ascending urinary tract infection. Infect Immun 58:1120-1123
28. Bahrani-Mougeot FK, Buckles EL, Lockatell CV, Hebel JR, Johnson DE, Tang CM, Donnenberg MS (2002) Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract. Mol Microbiol 45:1079-1093
29. Cross AS, Gemski P, Sadoff JC, Orskov F, Orskov I (1984) The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis 149:184-193
30. Justice SS, Hung C, Theriot JA, Fletcher DA, Anderson GG, Footer MJ, Hultgren SJ (2004) Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA 101:1333-1338
31. Mysorekar Iu, Hultgren SJ (2006) Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA 103:14170-14175
32. Trautner BW, Darouiche RO (2004) Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control 32:177-183
33. Alexander C, Rietschel ET (2001) Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res 7:167-202
34. Uhlen P, Laestadius A, Jahnukainen T, Soderblom T, Backhed F, Celsi G, Brismar H, Normark S, Aperia A, Richter-Dahlfors A (2000) Alpha-haemolysin of uropathogenic E. coli induces Ca2+ oscillations in renal epithelial cells. Nature 405:694-697
35. Fiorentini C, Matarrese P, Straface E, Falzano L, Donelli G, Boquet P, Malorni W (1998) Rho-dependent cell spreading activated by E. coli cytotoxic necrotizing factor 1 hinders apoptosis in epithelial cells. Cell Death Differ 5:921-929
36. Hofman P, Le Negrate G, Mograbi B, Hofman V, Brest P, Alliana-Schmid A, Flatau G, Boquet P, Rossi B (2000) Escherichia coli cytotoxic necrotizing factor-1 (CNF-1) increases the adherence to epithelia and the oxidative burst of human polymorphonuclear leukocytes but decreases bacteria phagocytosis. J Leukoc Biol 68:522-528
37. Johnson DE, Drachenberg C, Lockatell CV, Island MD, Warren JW, Donnenberg MS (2000) The role of cytotoxic necrotizing factor-1 in colonization and tissue injury in a murine model of urinary tract infection. FEMS Immunol Med Microbiol 28:37-41
38. Rippere-Lampe KE, O'Brien AD, Conran R, Lockman HA (2001) Mutation of the gene encoding cytotoxic necrotizing factor type 1 (cnf(1)) attenuates the virulence of uropathogenic Escherichia coli. Infect Immun 69:3954-3964
39. Guyer DM, Henderson IR, Nataro JP, Mobley HL (2000) Identification of sat, an autotransporter toxin produced by uropathogenic Escherichia coli. Mol Microbiol 38:53-66
40. Heimer SR, Rasko DA, Lockatell CV, Johnson DE, Mobley HL (2004) Autotransporter genes pic and tsh are associated with Escherichia coli strains that cause acute pyelonephritis and are expressed during urinary tract infection. Infect Immun 72:593-597
41. Jost SP, Gosling JA, Dixon JS (1989) The morphology of normal human bladder urothelium. J Anat 167:103-115
42. Staehelin LA, Chlapowski FJ, Bonneville MA (1972) Lumenal plasma membrane of the urinary bladder. I. Three-dimensional reconstruction from freeze-etch images. J Cell Biol 53:73-91
43. Hicks RM (1966) The function of the golgi complex in transitional epithelium. Synthesis of the thick cell membrane. J Cell Biol 30:623-643
44. Lewis SA (2000) Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 278:F867-874
45. Apodaca G (2004) The uroepithelium: not just a passive barrier. Traffic 5:117-128
46. Parsons CL, Greenspan C, Moore SW, Mulholland SG (1977) Role of surface mucin in primary antibacterial defense of bladder. Urology 9:48-52
47. Grist M, Chakraborty J (1994) Identification of a mucin layer in the urinary bladder. Urology 44:26-33
48. N'Dow J, Jordan N, Robson CN, Neal DE, Pearson JP (2005) The bladder does not appear to have a dynamic secreted continuous mucous gel layer. J Urol 173:2025-2031
49. Spencer JR, Schaeffer AJ (1986) Pediatric urinary tract infections. Urol Clin North Am 13:661-672
50. Fanos V, Cataldi L (2004) Antibiotics or surgery for vesicoureteric reflux in children. Lancet 364:1720-1722
51. Wennerstrom M, Hansson S, Jodal U, Stokland E (2000) Primary and acquired renal scarring in boys and girls with urinary tract infection. J Pediatr 136:30-34
52. Hellerstein S (2000) Long-term consequences of urinary tract infections. Curr Opin Pediatr 12:125-128
53. Garin EH, Olavarria F, Nieto VG, Valenciano B, Campos A, Young L (2006) Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 117:626-632
54. Wheeler DM, Vimalachandra D, Hodson EM, Roy LP, Smith GH, Craig JC (2004) Interventions for primary vesicoureteric reflux. Cochrane Database Syst Rev 3(CD001532)
55. Bakker E, van Gool J, van Sprundel M, van der Auwera JC, Wyndaele JJ (2004) Risk factors for recurrent urinary tract infection in 4,332 Belgian schoolchildren aged between 10 and 14 years. Eur J Pediatr 163:234-238
56. Saedi NA, Schulman SL (2003) Natural history of voiding dysfunction. Pediatr Nephrol 18:894-897
57. Greenfield SP, Wan J (2000) The relationship between dysfunctional voiding and congenital vesicoureteral reflux. Curr Opin Urol 10:607-610
58. Gordon DM, Riley MA (1992) A theoretical and experimental analysis of bacterial growth in the bladder. Mol Microbiol 6:555-562
59. Norden CW, Green GM, Kass EH (1968) Antibacterial mechanisms of the urinary bladder. J Clin Invest 47:2689-2700
60. Schenk EA, Schwartz RH, Lewis RA (1971) Tamm-Horsfall mucoprotein. I. Localization in the kidney. Lab Invest 25:92-95
61. Pennica D, Kohr WJ, Kuang WJ, Glaister D, Aggarwal BB, Chen EY, Goeddel DV (1987) Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science 236:83-88
62. Orskov I, Ferencz A, Orskov F (1980) Tamm-Horsfall protein or uromucoid is the normal urinary slime that traps type 1 fimbriated Escherichia coli. Lancet 1:887
63. Pak J, Pu Y, Zhang ZT, Hasty DL, Wu XR (2001) Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 276:9924-9930
64. Stein P, Rajasekaran M, Parsons CL (2005) Tamm-Horsfall protein protects urothelial permeability barrier. Urology 66:903-907
65. Yu CL, Lin WM, Liao TS, Tsai CY, Sun KH, Chen KH (1992) Tamm-Horsfall glycoprotein (THG) purified from normal human pregnancy urine increases phagocytosis, complement receptor expressions and arachidonic acid metabolism of polymorphonuclear neutrophils. Immunopharmacology 24:181-190
66. Horton JK, Davies M, Topley N, Thomas D, Williams JD (1990) Activation of the inflammatory response of neutrophils by Tamm-Horsfall glycoprotein. Kidney Int 37:717-726
67. Saemann MD, Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y, Stulnig TM, Akira S, von Gabain A, von Ahsen U, Horl WH, Zlabinger GJ (2005) Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest 115:468-475
68. Serafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42:658-676
69. Mo L, Zhu XH, Huang HY, Shapiro E, Hasty DL, Wu XR (2004) Ablation of the Tamm-Horsfall protein gene increases susceptibility of mice to bladder colonization by type 1-fimbriated Escherichia coli. Am J Physiol Renal Physiol 286:F795-802
70. Bates JM, Raffi HM, Prasadan K, Mascarenhas R, Laszik Z, Maeda N, Hultgren SJ, Kumar S (2004) Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 65:791-797
71. Bueler MR, Wiederkehr F, Vonderschmitt DJ (1995) Electrophoretic, chromatographic and immunological studies of human urinary proteins. Electrophoresis 16:124-134
72. Hamburger AE, Bjorkman PJ, Herr AB (2006) Structural insights into antibody-mediated mucosal immunity. Curr Top Microbiol Immunol 308:173-204
73. James-Ellison MY, Roberts R, Verrier-Jones K, Williams JD, Topley N (1997) Mucosal immunity in the urinary tract: changes in sIgA, FSC and total IgA with age and in urinary tract infection. Clin Nephrol 48:69-78
74. Fliedner M, Mehls O, Rauterberg EW, Ritz E (1986) Urinary sIgA in children with urinary tract infection. J Pediatr 109:416-421
75. Riedasch G, Heck P, Rauterberg E, Ritz E (1983) Does low urinary sIgA predispose to urinary tract infection? Kidney Int 23:759-763
76. Floege J, Boddeker M, Stolte H, Koch KM (1990) Urinary IgA, secretory IgA and secretory component in women with recurrent urinary tract infections. Nephron 56:50-55
77. Marild S, Hansson S, Jodal U, Oden A, Svedberg K (2004) Protective effect of breastfeeding against urinary tract infection. Acta Paediatr 93:164-168
78. Abrink M, Larsson E, Gobl A, Hellman L (2000) Expression of lactoferrin in the kidney: implications for innate immunity and iron metabolism. Kidney Int 57:2004-2010
79. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M (1992) Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73:472-479
80. Singh PK, Parsek MR, Greenberg EP, Welsh MJ (2002) A component of innate immunity prevents bacterial biofilm development. Nature 417:552-555
81. He J, Furmanski P (1995) Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373:721-724
82. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389-395
83. Schneider JJ, Unholzer A, Schaller M, Schafer-Korting M, Korting HC (2005) Human defensins. J Mol Med 83:587-595
84. Zaiou M, Gallo RL (2002) Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med 80:549-561
85. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB Jr, Ganz T (1998) Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 101:1633-1642
86. Lehmann J, Retz M, Harder J, Krams M, Kellner U, Hartmann J, Hohgrawe K, Raffenberg U, Gerber M, Loch T, Weichert-Jacobsen K, Stockle M (2002) Expression of human beta-defensins 1 and 2 in kidneys with chronic bacterial infection. BMC Infect Dis 2:20
87. Morrison G, Kilanowski F, Davidson D, Dorin J (2002) Characterization of the mouse beta defensin 1, Defb1, mutant mouse model. Infect Immun 70:3053-3060
88. Chromek M, Slamova Z, Bergman P, Kovacs L, Podracka L, Ehren I, Hokfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A (2006) The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 12:636-641
89. Perron GG, Zasloff M, Bell G (2006) Experimental evolution of resistance to an antimicrobial peptide. Proc Biol Sci 273:251-256
90. Backhed F, Soderhall M, Ekman P, Normark S, Richter-Dahlfors A (2001) Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ- and cell-specific expression of Toll-like receptors within the human urinary tract. Cell Microbiol 3:153-158
91. Samuelsson P, Hang L, Wullt B, Irjala H, Svanborg C (2004) Toll-like receptor 4 expression and cytokine responses in the human urinary tract mucosa. Infect Immun 72:3179-3186
92. Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT (2003) Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem 278:48313-48320
93. Chromek M, Stankowska D, Dadfar E, Kaca W, Rabbani H, Brauner A (2005) Interleukin-8 response in cells from the human urinary tract induced by lipopolysaccharides of Proteus mirabilis O3 and O18. J Urol 173:1381-1384
94. Schilling JD, Martin SM, Hunstad DA, Patel KP, Mulvey MA, Justice SS, Lorenz RG, Hultgren SJ (2003) CD14- and Toll-like receptor-dependent activation of bladder epithelial cells by lipopolysaccharide and type 1 piliated Escherichia coli. Infect Immun 71:1470-1480
95. Hedlund M, Frendeus B, Wachtler C, Hang L, Fischer H, Svanborg C (2001) Type 1 fimbriae deliver an LPS- and TLR4-dependent activation signal to CD14-negative cells. Mol Microbiol 39:542-552
96. Frendeus B, Wachtler C, Hedlund M, Fischer H, Samuelsson P, Svensson M, Svanborg C (2001) Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation. Mol Microbiol 40:37-51
97. Bergsten G, Samuelsson M, Wullt B, Leijonhufvud I, Fischer H, Svanborg C (2004) PapG-dependent adherence breaks mucosal inertia and triggers the innate host response. J Infect Dis 189:1734-1742
98. Eden CS, Hanson LA, Jodal U, Lindberg U, Akerlund AS (1976) Variable adherence to normal human urinary-tract epithelial cells of Escherichia coli strains associated with various forms of urinary-tract infection. Lancet 1:490-492
99. Bussolati B, David S, Cambi V, Tobias PS, Camussi G (2002) Urinary soluble CD14 mediates human proximal tubular epithelial cell injury induced by LPS. Int J Mol Med 10:441-449
100. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA, Ghosh S (2004) A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303:1522-1526
101. Brauner A, Soderhall M, Jacobson SH, Lundahl J, Andersson U, Andersson J (2001) Escherichia coli-induced expression of IL-1 alpha, IL-1 beta, IL-6 and IL-8 in normal human renal tubular epithelial cells. Clin Exp Immunol 124:423-428
102. Chowdhury P, Sacks SH, Sheerin NS (2004) Minireview: functions of the renal tract epithelium in coordinating the innate immune response to infection. Kidney Int 66:1334-1344
103. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE (2006) Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7:1250-1257
104. Engel D, Dobrindt U, Tittel A, Peters P, Maurer J, Gutgemann I, Kaissling B, Kuziel W, Jung S, Kurts C (2006) Tumor necrosis factor alpha- and inducible nitric oxide synthase-producing dendritic cells are rapidly recruited to the bladder in urinary tract infection but are dispensable for bacterial clearance. Infect Immun 74:6100-6107
105. Mellman I, Steinman RM (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255-258
106. Poljakovic M, Svensson ML, Svanborg C, Johansson K, Larsson B, Persson K (2001) Escherichia coli-induced inducible nitric oxide synthase and cyclooxygenase expression in the mouse bladder and kidney. Kidney Int 59:893-904
107. Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, Heuser J, Hultgren SJ (1998) Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282:1494-1497
108. Khalil A, Brauner A, Bakhiet M, Burman LG, Jaremko G, Wretlind B, Tullus K (1997) Cytokine gene expression during experimental Escherichia coli pyelonephritis in mice. J Urol 158:1576-1580
109. Godaly G, Proudfoot AE, Offord RE, Svanborg C, Agace WW (1997) Role of epithelial interleukin-8 (IL-8) and neutrophil IL-8 receptor A in Escherichia coli-induced transuroepithelial neutrophil migration. Infect Immun 65:3451-3456
110. Haraoka M, Hang L, Frendeus B, Godaly G, Burdick M, Strieter R, Svanborg C (1999) Neutrophil recruitment and resistance to urinary tract infection. J Infect Dis 180:1220-1229
111. Frendeus B, Godaly G, Hang L, Karpman D, Lundstedt AC, Svanborg C (2000) Interleukin 8 receptor deficiency confers susceptibility to acute experimental pyelonephritis and may have a human counterpart. J Exp Med 192:881-890
112. Lee WL, Harrison RE, Grinstein S (2003) Phagocytosis by neutrophils. Microbes Infect 5:1299-1306
113. Svanborg Eden C, Briles D, Hagberg L, McGhee J, Michalec S (1984) Genetic factors in host resistance to urinary tract infection. Infection 12:118-123
114. Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113(Suppl 1A):5S-13S
115. Stokland E, Hellstrom M, Jacobsson B, Jodal U, Sixt R (1998) Evaluation of DMSA scintigraphy and urography in assessing both acute and permanent renal damage in children. Acta Radiol 39:447-452
116. Sharma K, Ziyadeh FN (1994) The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266:F829-F842
117. Eddy AA (2002) Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283:F209-F220
118. Chromek M, Tullus K, Hertting O, Jaremko G, Khalil A, Li YH, Brauner A (2003) Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatr Res 53:698-705
119. Chromek M, Tullus K, Lundahl J, Brauner A (2004) Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun 72:82-88
120. Lundstedt AC, Leijonhufvud I, Ragnarsdottir B, Karpman D, Andersson B, Svanborg C (2007) Inherited susceptibility to acute pyelonephritis: a family study of urinary tract infection. J Infect Dis 195:1227-1234
121. Zasloff M (2006) Fighting infections with vitamin D. Nat Med 12:388-390
122. Reid G, Bruce AW (2006) Probiotics to prevent urinary tract infections: the rationale and evidence. World J Urol 24:28-32
123. Li X, Lockatell CV, Johnson DE, Lane MC, Warren JW, Mobley HL (2004) Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis. Infect Immun 72:66-75
124. Langermann S, Ballou WR (2003) Development of a recombinant FimCH vaccine for urinary tract infections. Adv Exp Med Biol 539:635-648
125. Jepson RG, Mihaljevic L, Craig J (2004) Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2(CD001321)